Mike: So I know that there’s a lot of research that goes in and I hear from some of the treatments that I’ve been receiving that there seems to be quite a lot of discoveries being made of treatments that are available for other conditions that are then being applied to the MS area. Is that something that you’re seeing more of at the moment?
Professor David Baker, Neurologist: Well, I think in terms of repair, is a thing that we’re really, really interested in. And you can try and make a drug to cause repair and actually that was one of the low lights, actually, one of the new drugs had been tried as a repair agent and it looked like it failed. Now, I don’t necessarily think that it means that the drug doesn’t cause repair, I think we’ve got a lot to do to work out how to do trials. But at the same time, we’ve noticed by looking that there are number of pathways that make myelinating cells remyelinate and many of those are bog standard drugs that are used for other conditions. So we know they’re safe for human use, so they will hopefully be, some of those will come over. And in fact, there are trials ongoing and I heard this week that there’s a trial that will start in Cambridge in the New Year. So we are learning from other diseases and taking drugs from other diseases. And again, another thing we heard this week was somewhere where we had an epilepsy drug and it was shown to slow the rate of nerve loss down and actually our group actually also looked in the blood and we could actually see that the drug was working and slowing nerve loss. So that’s quite a positive thing.
Join the Shift.ms community: https://shift.ms/
Watch more videos here: